Compounds > n-(2-(diethylamino)ethyl)-4-iodobenzamide
Page last updated: 2024-12-07

n-(2-(diethylamino)ethyl)-4-iodobenzamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(2-(diethylamino)ethyl)-4-iodobenzamide: RN refers to unlabled cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129424
CHEMBL ID13564
SCHEMBL ID1209964
MeSH IDM0183585

Synonyms (19)

Synonym
NCI60_022566
nsc665367
benzamide, n-(2-(diethylamino)ethyl)-4-iodo-
n-diethylamino-2 ethyl iodo-4-benzamide
deib
n-(2-diethylaminoethyl)-4-iodobenzamide
(123i)idab
n-(2-(diethylamino)ethyl)-4-iodobenzamide
i-bza
n-(2-(diethylamino)ethyl)-4-iodobenzamide hydrochloride
n-(2-diethylaminoethyl)-4-iodo-benzamide
CHEMBL13564
106790-96-9
AKOS008916151
SCHEMBL1209964
DTXSID60147768
Z27720938
n-[2-(diethylamino)ethyl]-4-iodobenzamide
EN300-1695994

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Similar side effect intensity of BZA2 and dacarbazine was observed, whereas BZA1 was more toxic."( Alkylating benzamides with melanoma cytotoxicity: experimental chemotherapy in a mouse melanoma model.
Bauder-Wüst, U; Eisenhut, M; Eskerski, H; Haberkorn, U; Wolf, M, 2006)		0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID407867Drug excretion in mouse B16-F0 cells bearing C57BL/6 mouse urine at 0.74 to 0.92 MBq, iv after 72 hrs2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.
AID408136Ratio of drug level in tumor to lung of C57BL/6 mouse bearing mouse B16-F0 cells at 0.74 to 0.92 MBq, iv after 6 hrs2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.
AID408138Ratio of drug level in tumor to brain of C57BL/6 mouse bearing mouse B16-F0 cells at 0.74 to 0.92 MBq, iv after 1 hr2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.
AID408134Ratio of drug level in tumor to lung of C57BL/6 mouse bearing mouse B16-F0 cells at 0.74 to 0.92 MBq, iv after 1 hr2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.
AID408139Ratio of drug level in tumor to brain of C57BL/6 mouse bearing mouse B16-F0 cells at 0.74 to 0.92 MBq, iv after 3 hrs2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.
AID407871Biodistribution in tumor of C57BL/6 mouse bearing mouse B16-F0 cells at 0.74 to 0.92 MBq, iv after 6 hrs2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.
AID407868Drug excretion in mouse B16-F0 cells bearing C57BL/6 mouse feces at 0.74 to 0.92 MBq, iv after 72 hrs2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.
AID39881Binding of radioiodinated compound in B16 cells as a function of specific activity for melanoma at 6 hr after injecting at 1.5*10e-3 (uMol/mouse).2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization.
AID408129Ratio of drug level in tumor to liver of C57BL/6 mouse bearing mouse B16-F0 cells at 0.74 to 0.92 MBq, iv after 1 hr2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.
AID407865Binding affinity to melanin in phosphate buffer solution2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.
AID407866Partition coefficient, log P in phosphate buffer solution at pH 7.42008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.
AID39871Binding of radioiodinated compound in B16 cells as a function of specific activity for blood at 1 hr after injecting at 1.5(umol/mouse).2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization.
AID39878Binding of radioiodinated compound in B16 cells as a function of specific activity for melanoma at 1 hr after injecting at 1.5(umol/mouse).2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization.
AID408130Ratio of drug level in tumor to liver of C57BL/6 mouse bearing mouse B16-F0 cells at 0.74 to 0.92 MBq, iv after 3 hrs2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.
AID408126Biodistribution in tumor of C57BL/6 mouse bearing mouse B16-F0 cells at 0.74 to 0.92 MBq, iv after 24 hrs2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.
AID408131Ratio of drug level in tumor to liver of C57BL/6 mouse bearing mouse B16-F0 cells at 0.74 to 0.92 MBq, iv after 6 hrs2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.
AID39872Binding of radioiodinated compound in B16 cells as a function of specific activity for blood at 1 hr after injecting at 1.5*10e-3 (uMol/mouse).2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization.
AID39876Binding of radioiodinated compound in B16 cells as a function of specific activity for blood at 6 hr after injecting at 1.8*10e-6 (uMol/mouse).2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization.
AID39882Binding of radioiodinated compound in B16 cells as a function of specific activity for melanoma at 6 hr after injecting at 1.8*10e-6 (uMol/mouse).2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization.
AID407864Binding affinity to melanin in water2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.
AID39879Binding of radioiodinated compound in B16 cells as a function of specific activity for melanoma at 1 hr after injecting at 1.5*10e-3 (uMol/mouse).2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization.
AID408127Biodistribution in tumor of C57BL/6 mouse bearing mouse B16-F0 cells at 0.74 to 0.92 MBq, iv after 72 hrs2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.
AID408128Half life in mouse B16-F0 cells bearing C57BL/6 mouse tumor at 0.74 to 0.92 MBq, iv2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.
AID408132Ratio of drug level in tumor to liver of C57BL/6 mouse bearing mouse B16-F0 cells at 0.74 to 0.92 MBq, iv after 24 hrs2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.
AID407870Biodistribution in tumor of C57BL/6 mouse bearing mouse B16-F0 cells at 0.74 to 0.92 MBq, iv after 3 hrs2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.
AID39873Binding of radioiodinated compound in B16 cells as a function of specific activity for blood at 1 hr after injecting at 1.8*10e-6 (uMol/mouse).2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization.
AID130277Amount of urinary radioactivity collected within 4 hr after iv injection into C57B1/6 mice was analyzed by RP-HPLC.2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization.
AID39880Binding of radioiodinated compound in B16 cells as a function of specific activity for melanoma at 6 hr after injecting at 1.5(umol/mouse).2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization.
AID408135Ratio of drug level in tumor to lung of C57BL/6 mouse bearing mouse B16-F0 cells at 0.74 to 0.92 MBq, iv after 3 hrs2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.
AID407869Biodistribution in tumor of C57BL/6 mouse bearing mouse B16-F0 cells at 0.74 to 0.92 MBq, iv after 1 hr2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma.
AID39874Binding of radioiodinated compound in B16 cells as a function of specific activity for blood at 6 hr after injecting at 1.5(umol/mouse).2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization.
AID39875Binding of radioiodinated compound in B16 cells as a function of specific activity for blood at 6 hr after injecting at 1.5*10e-3 (uMol/mouse)2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization.
AID39877Binding of radioiodinated compound in B16 cells as a function of specific activity for melanoma after 1 hr injecting at 1.8*10e-6 (uMol/mouse).2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's14 (46.67)18.2507
2000's9 (30.00)29.6817
2010's0 (0.00)24.3611
2020's7 (23.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.63 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (12.50%)5.53%
Reviews1 (3.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (84.38%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chlorambucil
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.		2.0310aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
haloperidol
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.		2.4120aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
iofetamine
Iofetamine: An amphetamine analog that is rapidly taken up by the lungs and from there redistributed primarily to the brain and liver. It is used in brain radionuclide scanning with I-123.		1.9710
1,3-ditolylguanidine
1,3-ditolylguanidine: structure given in first source; a selective ligand for the sigma binding sites in the brain		210toluenes
4-iodo-n-piperidinoethylbenzamide
4-iodo-N-piperidinoethylbenzamide: a malignant melanoma imaging agent; structure given in first source		2.3920carbonyl compound;
organohalogen compound
technetium tc 99m pentetate
Technetium Tc 99m Pentetate: A technetium imaging agent used in renal scintigraphy, computed tomography, lung ventilation imaging, gastrointestinal scintigraphy, and many other procedures which employ radionuclide imaging agents.		1.9810
piperidines
Piperidines: A family of hexahydropyridines.		2.3920
dacarbazine
(E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.		2.0310dacarbazine
ConditionIndicatedRelationship StrengthStudiesTrials
Malignant Melanoma
[description not available]		06.64154
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		06.64154
B16 Melanoma
[description not available]		03.3870
Cancer of Eye
[description not available]		03.411
Cancer of Liver
[description not available]		04.9933
Cancer of Skin
[description not available]		05.0452
Choroid Neoplasms
Tumors of the choroid; most common intraocular tumors are malignant melanomas of the choroid. These usually occur after puberty and increase in incidence with advancing age. Most malignant melanomas of the uveal tract develop from benign melanomas (nevi).		04.6332
Conjunctival Neoplasms
Tumors or cancer of the CONJUNCTIVA.		04.3622
Liver Neoplasms
Tumors or cancer of the LIVER.		04.9933
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		05.5563
Skin Neoplasms
Tumors or cancer of the SKIN.		05.0452
Uveal Neoplasms
Tumors or cancer of the UVEA.		04.6432
Cancer of Lung
[description not available]		05.0452
Lung Neoplasms
Tumors or cancer of the LUNG.		05.0452
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0310
Lymph Node Metastasis
[description not available]		03.3711
Neoplasm Metastasis, Unknown Primary
[description not available]		03.3711
Metastase
[description not available]		03.3711
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		03.3711
Mole, Skin
[description not available]		01.9910
Iris Neoplasms
Tumors of the iris characterized by increased pigmentation of melanocytes. Iris nevi are composed of proliferated melanocytes and are associated with neurofibromatosis and malignant melanoma of the choroid and ciliary body. Malignant melanoma of the iris often originates from preexisting nevi.		01.9910
Invasiveness, Neoplasm
[description not available]		01.9910
Carcinoma, Oat Cell
[description not available]		0210
Carcinoma, Small Cell
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)		0210